FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.
You may also be interested in...
Schering-Plough Hopes To Enhance Confidence In Vytorin/Zetia With Monthly Rx Data
Firm feeling impact on sales from Vytorin study results.
Schering-Plough Hopes To Enhance Confidence In Vytorin/Zetia With Monthly Rx Data
Firm feeling impact on sales from Vytorin study results.
Organon Asenapine Study Shows Improved Effect On Negative Schizophrenia Symptoms Over Risperdal
Patients treated with asenapine also experienced less weight gain and lower levels of prolactin, a signal associated with improved sexual side effects.